At the expected clinical dose of 2.5mg/kg once daily, MRX-8 demonstrated potential for best therapeutic effects against resistant infections. Credit: Kateryna Kon / Shutterstock.

Shanghai MicuRx Pharmaceuticals has announced the successful conclusion of the Phase I clinical trial of its antibacterial drug MRX-8 in China, meeting the expected goals.

A new injectable polymyxin antibacterial agent, MRX-8 is intended for treating infections caused by multi-drug-resistant Gram-negative bacteria.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The double-blind, randomised, placebo-controlled study, including single ascending dose and multiple ascending dose components, aimed to assess the drug’s safety, tolerability, and pharmacokinetics in healthy Chinese adults.

According to the findings, the drug exposure of MRX-8 in the human body was found to be dose-proportional.

At the expected clinical dose of 2.5mg/kg once daily, MRX-8 demonstrated the potential for the best therapeutic effects against resistant infections.

Throughout the trial, MRX-8 showed a good safety profile, without any participants withdrawing due to adverse events and no severe adverse events were reported.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Mild sensory reduction and reduced glomerular filtration rate were the most common adverse events seen in the trial, which resolved without needing any intervention.

Only two participants in the multiple-dose portion experienced CTCAE Grade 2 adverse events related to the injection site.

MicuRx plans to integrate findings from both US and China Phase I trials to advance MRX-8’s clinical development.

The company is actively exploring development pathways for various indications, aiming to deliver a new antibacterial drug for treating infections caused by multidrug-resistant Gram-negative bacteria.

According to the data from a Phase I trial completed in the US in 2022, MRX-8 demonstrated to attain ideal therapeutic effects against infections caused by multidrug-resistant Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii.